The purpose of this project is to further our understanding of the mechanisms of cell-extracellular matrix interactions which regulate cell behavior during tumor progression and angiogenesis. In particular we are interested in the regulation of cell invasion and cell growth. These processes require remodeling of the extracellular matrix that occurs in a spatially and temporally controlled fashion. This involves both proteases and protease inhibitor activities that are tightly regulated. The tissue inhibitor of metalloproteinase (TIMP) family consists of four members: TIMP-1, TIMP-2, TIMP-3 and TIMP-4. All TIMP family members are secreted into the extracellular milieu and have a similar size core protein of 182-194 amino acids with 12 cysteine residues that form six intramolecular disulfides. Correct folding of the peptide backbone and formation of these disulfide bonds are required for functional MMP inhibitor activity. MMP inhibitor activity is further localized to the three amino-terminal disulfide loops and requires a free amino terminal cysteine residue. Studies have shown that the transcription of individual TIMPs are regulated independently of one another. TIMPs inhibit cell invasion (both tumor and endothelial cells) through reconstituted basement membranes in vitro, principally via inhibition of metalloproteinase activity. Both TIMP-1 and TIMP-2 demonstrate cell growth regulating and erythroid potentiating activities (EPA) that appear to be functionally distinct from inhibition of proteases.
The specific aims of these studies are: 1) to understand the relationship of protease inhibitor activity to the growth regulating activity of TIMPs; 2) to define the mechanisms through which individual members of the TIMP family regulate cell growth. To accomplish these goals we have developed a series of modified TIMP proteins and expression vectors, as well as both in vitro and in vivo models to examine the effects of TIMPs on cell growth. Using these reagents and model systems we have demonstrated that modulation of endothelial and tumor cell growth by TIMPs in vitro and in vivo is independent of the protease inhibitor activity of these proteins. In addition, direct cell surface binding of TIMPs has been demonstrated suggesting the presence of putative cell surface receptors for these extracellular matrix protease inhibitors. Signal transduction studies suggest that TIMP binding activates adenylate cyclase, protein kinase A and the protein tyrosine phosphatase SHP-1. Further experiments are directed at: 1) identification and characterization of TIMP receptors; 2) identification of specific peptide sequences responsible for the cell growth modulating properties of TIMPs; 3) proteomic and cDNA microarray characterization of cellular responses to TIMPs both in vitro and in vivo. Our findings confirm the antiangiogenic activity of TIMPs, as well as a unique growth inhibitory activity of TIMP-2 on human microvascular endothelial cells. Identification and characterization of TIMP-2-derived peptide sequences, and/or TIMP receptors may lead to development of novel anticancer therapies.

Agency
National Institute of Health (NIH)
Institute
Division of Clinical Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC009179-13
Application #
6558486
Study Section
(LP)
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kim, Soo Hyeon; Cho, Young-Rak; Kim, Hyeon-Ju et al. (2012) Antagonism of VEGF-A-induced increase in vascular permeability by an integrin ?3?1-Shp-1-cAMP/PKA pathway. Blood 120:4892-902
Guedez, Liliana; Jensen-Taubman, Sandra; Bourboulia, Dimitra et al. (2012) TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. J Immunother 35:502-12
Seo, Dong-Wan; Saxinger, W Carl; Guedez, Liliana et al. (2011) An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo. Peptides 32:1840-8
Lee, Seo-Jin; Tsang, Patricia S; Diaz, Tere M et al. (2010) TIMP-2 modulates VEGFR-2 phosphorylation and enhances phosphodiesterase activity in endothelial cells. Lab Invest 90:374-82
Bourboulia, Dimitra; Stetler-Stevenson, William G (2010) Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 20:161-8
Alper, Ozge; Stetler-Stevenson, William G; Harris, Lyndsay N et al. (2009) Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci 100:1748-56
Seo, Dong-Wan; Kim, Soo Hyeon; Eom, Seok-Hyun et al. (2008) TIMP-2 disrupts FGF-2-induced downstream signaling pathways. Microvasc Res 76:145-51
Kim, Young-Sik; Seo, Dong-Wan; Kong, Su-Kang et al. (2008) TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation. Cancer Lett 269:37-45
Lee, Hongsik; Lim, Chaeseung; Lee, Jungeun et al. (2008) TGF-beta signaling preserves RECK expression in activated pancreatic stellate cells. J Cell Biochem 104:1065-74
Stetler-Stevenson, William G (2008) Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 1:re6

Showing the most recent 10 out of 34 publications